Ischemic Heart Disease (IHD) has been recognized as the main cause of mortality in the modern world. Application of cell therapy technologies for the IHD treatment has been actively studied from the beginning of 2000s. The review is dedicated to the use of mesenchymal stem cells (MSC) in the therapy of IHD. The strategies of the MSC modification in vitro for improvement of their regenerative potential are extensively discussed, including preconditioning to enhance the cell survival, boosting their paracrine effect and manipulating their cardiomyogenic differentiation. The optimization of the MSC delivery and opportunities related to the use of biomaterials as cell carriers are also discussed. The results of the most important clinical studies on the MSC-based IHD therapy are presented, including those completed and published in the literature and the ongoing clinical trials registered at clinicaltrials.gov by June 2018.
Keywords: Ischemic heart disease, mesenchymal stem cells, cell therapy, regenerative medicine, clinical trials, MSC-based IHD.
Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry Hypoglycemia and Cardiac Arrhythmia; Mechanisms, Evidence Base a nd Current Recommendations
Current Diabetes Reviews Onco-Surgical Management of Colo-Rectal Liver Metastases in Older Patients: A New Frontier in the 3<sup>rd</sup> Millennium
Anti-Cancer Agents in Medicinal Chemistry Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design Significant Overlapping Modules and Biological Processes Between Stroke and Coronary Heart Disease
CNS & Neurological Disorders - Drug Targets Application of Mitochondria-Targeted Pharmaceuticals for the Treatment of Heart Disease
Current Pharmaceutical Design Preclinical Testing of Drug-Induced Proarrhythmia: Value of Transgenic Models
Cardiovascular & Hematological Agents in Medicinal Chemistry Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
Current Cardiology Reviews HMG-Co A Reductase Inhibitors in the Treatment of Cardiovascular Diseases: Stabilization of Coronary Artery Plaque
Current Drug Targets The Therapeutical Effect of Chinese Medicine for the Treatment of Atherosclerotic Coronary Heart Disease
Current Pharmaceutical Design The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Autophagy and Heart Disease: Implications for Cardiac Ischemia- Reperfusion Damage
Current Molecular Medicine Biomimetic Approaches for Targeted Nanomedicine: Current Status and Future Perspectives
Current Drug Therapy Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?]
Current Vascular Pharmacology Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology Brain Angiotensin and Cardiovascular Reactivity to Negative and Positive Emotional Stress
Current Hypertension Reviews Practical Recommendations for Familial Combined Hyperlipidemia Diagnosis and Management: An Update
Vascular Disease Prevention CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation